Nexalis Therapeutics Limited (ASX:NX1)

Market Cap	6.07M -28.9%
Revenue (ttm)	986.43K +145.5%
Net Income	-1.62M
EPS	-0.01
Shares Out	253.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,228
Average Volume	98,410
Open	0.0240
Previous Close	n/a
Day's Range	0.0240 - 0.0240
52-Week Range	0.0170 - 0.0480
Beta	0.14
RSI	53.38
Earnings Date	May 22, 2026

About Nexalis Therapeutics

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limit...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NX1

Financial Performance

In 2025, Nexalis Therapeutics's revenue was 986,434, an increase of 145.50% compared to the previous year's 401,811. Losses were -1.62 million, 33.9% more than in 2024.